NASDAQ · PHARMACEUTICAL PREPARATIONS
Nexentis Technologies Inc. NXTS
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-8.61
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-38.6%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 8-year series below
Revenue
Net income
Per share
USD -8.61
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-38.6%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-31.0%
Each USD of equity lost 39 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+3.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−21.7%
+3.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 20.4M
total assets, end of FY2025
Total assetsUSD 20.4M
EquityUSD 16.0M
CashUSD 3.8M
Gross debtUSD 1.2M
Net debtUSD -2.6M
Current ratio4.19×
The company holds more cash than debt.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−8.61
−27.74
−5.43
−10.85
−2.06
−1.05
−1.38
−0.05
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
−38.6
−92.5
−105.8
−93.1
−159.4
·
·
−163.5
Shares out B
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
31 of 31
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed